These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35508862)

  • 1. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction.
    Chen Y; Xu YY; Jiang HJ; Wang L; Zhai JW; Zhang T; Yang YF
    Chin J Integr Med; 2022 Oct; 28(10):924-929. PubMed ID: 35508862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study.
    Wang F; Yuan X; Jia J; Bi X; Zhou Z; Zhou Q; Li X; Luo C; Deng M; Yi L; Li Y; Lu J; Su W; Chen H; Zhu Y; Wang S
    Sci Rep; 2020 Apr; 10(1):6058. PubMed ID: 32269247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study.
    Li N; Deng W; Zhang G; Du Y; Guo Y; Ma Y; Wei C; Bie L; Zhang C; Song T; Luo S; Fang B
    Front Oncol; 2021; 11():728854. PubMed ID: 34540697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
    Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
    Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
    Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
    Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
    Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.
    Gou M; Si H; Zhang Y; Qian N; Wang Z; Shi W; Dai G
    Sci Rep; 2018 Mar; 8(1):4602. PubMed ID: 29545575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
    Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
    J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
    Liu Y; Hu X; Jiang J; Yang L; Zhou S; Liu P; Li J; Wang Y; Hao X; Shi Y
    Oncologist; 2020 May; 25(5):e833-e842. PubMed ID: 32250517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
    Wu Q; Fu Y; Wen W; Xi T; Zhao G
    J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.